Ascendis Pharma Growth Disorders A/S: Financial statements 2013
CVR: 32323677
Source: annual report 2013, Danish Business Authority
01/01/2013 – 31/12/2013
Ascendis Pharma Growth Disorders A/S (CVR 32323677) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK -22,831 and a net result of DKK -33,146. Equity in the 2013 report amounted to DKK 89,025. The solvency ratio was 7.3%.
- Gross Profit
- DKK -22,831
- Profit/Loss
- DKK -33,146
- Equity
- DKK 89,025
- Total Assets
- DKK 1,217,830
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2013
On November 28, 2013, the company changed its name from ACP 30.06.2012 4 A/S to ASCENDIS PHARMA RELAXIN DIVISION A/S.
Ascendis Pharma Growth Disorders A/S has published its interim report for the period June 29, 2012 to December 31, 2012.
About Ascendis Pharma Growth Disorders A/S
Ascendis Pharma Growth Disorders A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, CIRCULATORY DISEASES DIVISION A/S and ASCENDIS PHARMA RELAXIN DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -190,726,000 and a net result of EUR -225,725,000 compared with EUR -176,019,000 the year before. Equity in the 2025 report amounted to EUR -723,740,000.
